Loading stock data…
ACET
$8.20+0.65 (+8.61%)
Market ClosedLast close May 1
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adicet Bio, Inc. in the Healthcare sector is trading at $8.20. The stock is currently near its 52-week low of $6.01, remaining 16.3% below its 200-day moving average. Technical signals show neutral RSI of 70 and bullish MACD crossover, explaining why ACET maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.20
Potential Upside
5%
Whystock Fair Value$8.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$38.00+363.4%
Range$18.00 – $100.00
Fundamentals
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel),...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$79.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.00%
Volume
Today's trading volume
118,994
Recent News
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year?
Here is how Exact Sciences (EXAS) and Adicet Bio, Inc. (ACET) have performed compared to their sector so far this year.
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
MaxCyte, Inc. (NASDAQ:MXCT) is one of the Best 52-Week Low Penny Stocks to Buy Now. On August 4, MaxCyte, Inc. (NASDAQ:MXCT) announced signing a strategic platform license with Adicet Bio, Inc. Adicet focuses on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. As part of this agreement, Adicet gets non-exclusive rights to […]
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001
Participants who are enrolled will be given a dose of ADI-001, followed by a 28-day dose-limiting toxicity window.